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Circadian clock dysfunction is a common symptom
of aging and neurodegenerative diseases, though
its impact on brain health is poorly understood.
Astrocyte activation occurs in response to diverse in-
sults and plays a critical role in brain health and dis-
ease. We report that the core circadian clock protein
BMAL1 regulates astrogliosis in a synergisticmanner
via a cell-autonomous mechanism and a lesser non-
cell-autonomous signal from neurons. Astrocyte-
specific Bmal1 deletion induces astrocyte activation
and inflammatory gene expression in vitro and in vivo,
mediated in part by suppression of glutathione-S-
transferase signaling. Functionally, loss of Bmal1 in
astrocytes promotes neuronal death in vitro. Our re-
sults demonstrate that the core clock protein BMAL1
regulates astrocyte activation and function in vivo,
elucidating a mechanism by which the circadian
clock could influence many aspects of brain function
and neurological disease.
INTRODUCTION
Changes in behavioral circadian rhythms are common in many
neurodegenerative diseases (Breen et al., 2014; Hatfield et al.,
2004; Musiek and Holtzman, 2016) and can occur early in dis-
ease progression (Musiek et al., 2018). Circadian rhythms are
generated by the suprachiasmatic nucleus of the hypothalamus
(SCN) (Mohawk et al., 2012), which synchronizes cellular clocks
throughout the body to the light-dark (L:D) cycle. The core mo-
lecular clock consists of a transcriptional-translational feedback
loop with a positive transcriptional limb, consisting of hetero-
dimers of the basic-helix-loop-helix (bHLH) transcription factor
BMAL1 (also known as ARNTL [aryl hydrocarbon receptor nu-
clear translocator-like protein 1]) with either CLOCK (circadian
locomotor output cycles kaput) or NPAS2 (neuronal PAS domain
protein 2). The negative limb includes Period (PER), crypto-
chrome (CRY), and REV-ERB genes, which are transcriptional
targets of BMAL1 and provide negative feedback inhibition of
BMAL1 function (Mohawk et al., 2012). The core clock regulates
transcription of thousands of genes in a highly tissue-specific
manner, regulating cellular functions including metabolism,
inflammation, and redox homeostasis (Bass and Takahashi,
2010). In addition to disrupted activity and sleep rhythms, dysre-
gulated circadian gene expression patterns are also observed in
neurodegenerative disease models and patients (Song et al.,
2015; Breen et al., 2014; Cronin et al., 2017). However, the
impact of clock dysfunction on neurological diseases of the brain
remains poorly understood.
Astrocytes play a critical role in brain health and neurodegen-
erative disease, as dysfunctional astrocytes can drive neurode-
generation (Lian et al., 2015; Macauley et al., 2011; Yamanaka
et al., 2008). Astrocyte activation is a ubiquitous response to
brain injury, from neurodegeneration to trauma, which has histor-
ically been characterized by increased expression of the cyto-
skeletal protein glial fibrillary acidic protein (GFAP) (Sofroniew,
2014). Recent work has begun to elucidate the diversity of astro-
cyte activation phenotypes beyond GFAP, as astrocytes acti-
vated by different stimuli express unique transcriptional profiles
that can be associated with divergent phenotypes, ranging from
neurotoxic to neurotrophic (Liddelow et al., 2017; Zamanian
et al., 2012). However, a further understanding of astrocyte acti-
vation mechanisms is needed in order to effectively target astro-
cyte function therapeutically.
Astrocyte activation and circadian clock dysfunction are two
pervasive, often coexistent features of neurological diseases,
though their interaction is unknown. We previously observed
that deletion of the core clock gene Bmal1, which abrogates all
circadian clock function, caused severe, spontaneous astroglio-
sis throughout the mouse brain, which was accompanied by
increased oxidative stress, synaptic damage, and inflammation
(Musiek et al., 2013). However, the cellular and molecular mech-
anisms linking BMAL1 to astrocyte activation and function
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remain uncertain. Thus, we sought to characterize the astrocyte
activation induced by circadian clock disruption and evaluate
whether the clock protein BMAL1 might regulate astrogliosis in
a cell-autonomous manner.
RESULTS
We first asked if nongenetic disruption of circadian rhythms
could influence Gfap levels in the brain. Exposure of wild-type
(WT) C57BL/6 mice to a 10 hr:10 hr L:D cycle induces circadian
desynchrony and eventually arrhythmicity, as well as loss of
detectable circadian transcript oscillations in the cerebral cortex
(Figures 1A and S1A). After 6 weeks of circadian disruption,Gfap
transcript levels were increased throughout the circadian cycle
(Figure S1B), with an average increase of 19.7% (Figure 1B).
Thus, light-induced behavioral circadian rhythm disruption pro-
motes astrocyte Gfap expression.
We previously observed that abrogation of circadian function
by deletion of Bmal1 in mice induced striking increases in
GFAP+ astrocytes throughout the brain (Musiek et al., 2013;
Yang et al., 2016). We asked if the astrocyte activation observed
followingBmal1 deletionwas simply a response to neuronal injury
or a cell-autonomous process regulated by the core clock in as-
trocytes. To address this, we examined the brains of neuron-spe-
cific Bmal1 knockout (KO) mice (Camk2a-iCre;Bmal1f/f). These
mice express Cre recombinase in a pan-neuronal manner under
Figure 1. Light-Induced Circadian Disruption or Neuron-Specific Bmal1 Deletion Partially Recapitulates the Astrocyte Activation Phenotype
Observed following Brain-Specific Bmal1 Deletion
(A) Cortical qPCR from 6-week-old WT mice housed in 12 hr:12 hr or 10 hr:10 hr light-dark cycles for 6 weeks, harvested every 6 hr from CT6 to CT24, reveals
blunting of circadian gene oscillations in 10 hr:10 hr mice.
(B) Total Gfap mRNA levels for mice from (A). **p < 0.01 by 2-tailed t test.
(C) Representative images showing GFAP immunostaining of hippocampus (top) and cingulate cortex (bottom) of neuron-specific Bmal1 KO mice (Cam2a-
iCre+;Bmal1f/f) and brain-specific (neurons+astrocytes) Bmal1 KO mice (Nestin-Cre+;Bmal1f/f) at 4 months. Scale bar, 100 mm.
(D) Quantification of GFAP immunoreactivity in two brain regions of Cre, Cam2a-iCre+;Bmal1f/f, and Nestin-Cre+;Bmal1f/f mice. n = 3–4 mice per genotype.
Each data point represents 1 mouse. *p < 0.05 by 1-way ANOVA.
(E) Quantification of astrocyte activation transcripts by qPCR in the cortex of Cre;Bmal1f/f, Cam2a-iCre+;Bmal1f/f, and Nestin-Cre+;Bmal1f/f mice. The clock-
controlled geneNr1d1 is shown to illustrate loss of BMAL1-mediated transcription. *p < 0.05 by 2-way ANOVAwith Dunnett’s post-test for multiple comparisons.
All data represent mean ± SEM.
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the control of a BAC-CaMKIIa promoter, yielding widespread
neuronal deletion of Bmal1 (Figure S1C) and loss of behavioral
circadian rhythms (Izumo et al., 2014). At 4 months, Camk2a-
iCre+;Bmal1f/fmice exhibited amodest increase in astrocyte acti-
vation, as assessed by GFAP immunostaining (Figures 1C and
1D) and qPCR (Figure 1E), in the cortex and hippocampus. How-
ever, similarly aged Nestin-Cre+;Bmal1f/f (referred to as NBmal1
KO) mice, in which Bmal1 is deleted in neurons and astrocytes,
have much more prominent astrogliosis throughout the brain
and higher expression of the activation-related transcripts Aqp4
and Serpina3n (Figures 1C–1E). While NBmal1 KO mice exhibit
large increases in GFAP+ astrocytes in the cortex, this did not
appear to be due to increased astrocyte division, as NBmal1
KO mice had no significant increase in dividing Ki67+, GFAP+
double-positive cells (Figure S1D) or immunoreactivity for the
pan-astrocyte marker S100B (Figure S1E). This finding suggests
that while a small component of astrogliosis observed following
Bmal1 deletion may be a response to neuronal injury, BMAL1
within astrocytes appears to play a critical cell-autonomous role
in astrocyte activation.
To assess the potential cell-autonomous effects of Bmal1 on
astrocyte activation, we generated primary astrocyte-enriched
cultures from Bmal1 KO mice and WT littermates and examined
activation markers in vitro. Bmal1 KO astrocytes were viable and
appeared to have normal morphology but had significantly
elevated expression of Gfap and Aqp4mRNA and GFAP protein
(Figures 2A and 2B), suggesting spontaneous activation in the
absence of neuronal influence. In order to exclude a develop-
mental influence of BMAL1, we used small interfering RNA
(siRNA) to knock down Bmal1 expression in WT primary astro-
cyte cultures. This method resulted in a 95% decrease in
BMAL1 protein (Figures 2C and 2D) and a 66% decrease in
expression of the BMAL1 target Nr1d1 (which encodes REV-
ERBa) (Figure S2A). Bmal1 knockdown (KD) in astrocytes
induced a highly consistent (across 14 independent experi-
ments) 36% increase in Gfap mRNA expression (Figure S2A)
as well as a 68% increase in GFAP protein (Figures 2C and
2D). We also saw significant increases in the astrocyte activation
marker S100a6 (1.7-fold), the cytokine Il6 (2.4-fold), and Il33
(1.6-fold) (Figure S2A), an astrocytic cytokine implicated in
astrocyte-microglia signaling (Wicher et al., 2017). Bmal1 KD in
primary astrocytes from Per2-luciferase reporter mice caused
a loss of circadian Per2 rhythms (Figure 2E). Thus, disruption
of circadian function via KD of Bmal1 in WT astrocytes induces
a cell-autonomous reactive phenotype in vitro.
Wenext sought toconfirmthesefindingsbyspecificallydeleting
Bmal1 in astrocytes in vivo. We found that intracerebroventricular
injection of an AAV8 viral vector expressing EGFP under a Gfap
promoter (AAV8-GFAP-EGFP) on postnatal day 2 led to wide-
spread EGFP expression in resting astrocytes throughout the ce-
rebral cortex,withalmostnoneuronal labeling (Figures2F,2G,and
S2B). Thus, we injected P2Bmal1f/fmice either with AAV8-GFAP-
GFPorwith an identical virus expressing aCre-GFP fusion protein
(AAV8-GFAP-CreGFP). At 5 months, we observed Bmal1 deletion
and increased GFAP expression specifically in astrocytes ex-
pressing AAV8-GFAP-CreGFP (Figure 2F). The GFAP-CreGFP vec-
tor exhibits very weak nuclei-restricted fluorescence, making it
more difficult to see than that of the AAV8-GFAP-EGFP vector.
Mice treated with the EGFP control vector had widespread astro-
cyte labeling throughout the cingulate and retrosplenial cortices,
intact BMAL1 expression, and very little astrocyte activation as
defined by GFAP immunoreactivity (Figures 2F and 2G). Mice in-
jected with the CreGFP vector showed astrocytic nuclear GFP
expression and 3.4- and 3.1-fold increases inGFAP immunoreac-
tivity in the cingulate and retrosplenial cortices, respectively
(Figure 2G). Finally, we generated tamoxifen-inducible astrocyte-
specific Bmal1 KO mice using an Aldh1l1-CreERT2 driver line
(Aldh1l1-CreERT2;Bmal1f/f mice) (Srinivasan et al., 2016). We
treated Cre+ and Cre mice with tamoxifen at 1 month and
examined astrocyte activation at 3 months. We observed
specific deletion of Bmal1 in astrocyte nuclei of the hippocampus
and cortex (Figures S2D and S2E). Aldh1l1-Cre+ mice had signif-
icant increases in astrogliosis, as assessed by GFAP immuno-
staining in the hippocampus (Figure 2H), and a nearly significant
(p = 0.055) increase in the retrosplenial cortex (Figure S2C).
While it is difficult to directly compare tamoxifen-inducible and
constitutive Cre lines, Aldh1l1-Cre+ mice had similar levels of
astrogliosis to tamoxifen inducible global Bmal1 KO mice
(CAG-CreERT2+;Bmal1f/f) (Yang et al., 2016) also harvested
2 months after TAM treatment (Figures 2H and S2C). Astrogliosis
was not caused by Cre expression, as Cre+;Bmal1flox/wt mice
had no phenotype (Figures 2H and S2C). Ald1l1-Cre+ mice also
had spontaneous and significant increases in a number of
additional astrocyte activation transcripts including S100a6
(2.5-fold), C4b (2.6-fold), Cxcl5 (7.5-fold), and Mmp14 (3.1-fold)
(Figure S2F). In total, these experiments demonstrate that Bmal1
deletion in astrocytes can induce activation in a cell-autonomous
manner.
While activated astrocytes generally exhibit morphologic
changes and increasedGFAP expression, the transcriptional pro-
file of activated astrocytes is heterogeneous and can define their
function (Liddelow et al., 2017; Zamanian et al., 2012). In order to
examine the transcriptional profile in the brain following Bmal1
deletion, we performed microarray analysis of cortical tissue
from 11-month-old NBmal1 KO mice, Cre controls, and
Per1Brdm/Per2Brdm (Per1/2mut) mice placed in constant dark con-
ditions for 36 hr and then harvested at clock time (CT) 6:00 and
18:00. Per1/2mut mice were included because they have a
dysfunctional circadian clock but no astrogliosis phenotype as
well as tonically increased levels of BMAL1 transcriptional targets
(Figures 3A and S3A). To understand astrocyte transcriptional
changes in NBmal1 KO brain, we examined the overlap between
the 200 most upregulated transcripts in NBmal1 KO with the 200
most astrocyte-enriched transcripts according to the Barres lab
RNA-sequencing (RNA-seq) database (Zhang et al., 2014) (Fig-
ure 3A). Thirty genes overlapped, includingGfap, Aqp4 (encoding
the astrocytic water channel aquaporin-4), and Megf10, a gene
involved in astrocyte-mediated synaptic elimination (Chung
et al., 2013). C4b, a complement cascade component also impli-
cated in synapse elimination and a marker of astrocyte activation
and aging (Boisvert et al., 2018; Clarke et al., 2018), was strongly
upregulated (4-fold) in NBmal1 KO brain. Several other disease-
associated astrocytic genes were increased in NBmal1 KO brain,
including inflammatorymediators such asCxcl5 andCcr7 and the
matrix metalloproteinasesMmp14 andMmp2. Nearly all of these
transcripts were either unchanged or decreased in Per1/2mut
Cell Reports 25, 1–9, October 2, 2018 3
mice, demonstrating the key role of decreased BMAL1 function in
this phenotype. We next performedmicrofluidic qPCR profiling of
global Bmal1 KO hippocampal samples for markers of astrocyte
activation and polarization (Liddelow et al., 2017), which demon-
strated that Bmal1 deletion increased most pan-reactive markers
but did not clearly polarize astrocytes toward a neurotoxic or neu-
rotrophic profile (Figure 3B). These genetic profiling studies sug-
gest that Bmal1 deletion induces a unique state of astrocyte
activation.
Although Per1/2mut and NBmal1 KO mice are both behavior-
ally arrhythmic, expression of BMAL1 transcriptional targets
Nr1d1 and Dbp are elevated solely in Per1/2mut mice because
of loss of inhibition of BMAL1 (Figures 3A and S3A). Gfap is
not elevated inPer1/2mutmice (Figures 3A and S3A), suggesting
that loss of BMAL1 activity, or at least blunting of BMAL1 oscil-
lation (as in Figure 1A), is needed to induce astrocyte activation.
In order to determine if Gfap and other selected activation
markers are clock-controlled genes, we harvested cortex
Figure 2. Bmal1 Deficiency Induces Cell-Autonomous Astrocyte Activation In Vitro and In Vivo
(A) qPCR ofGfap and Aqp4mRNA in primary astrocyte-enriched cultures fromWT or global Bmal1 KOmice. n = 8–12 samples from 3 independent experiments.
(B) Western blot showing increased GFAP protein levels in cultured astrocyte cell lysates from Bmal1 KOmice. p42/44 ERK protein is shown as a loading control.
(C) Western blot showing knockdown of BMAL1 and increased GFAP protein in WT astrocyte cultures 7 days after treatment with non-targeting siRNA (siSCR) or
siRNA targeting Bmal1 (siBmal1). p42/44 ERK protein is shown as a loading control.
(D) Densitometric quantification of blots in (C). n = 4 samples/group.
(E) Representative trace depicting detrended circadian oscillations in luminescence seen in primary astrocyte cultures from Per2-Luc reporter mice treated with
siRNA (siSCR, blue; or siBmal1, red). Similar results were obtained in 3 separate cultures.
(F) Representative confocal images from cerebral cortex of Bmal1f/f mice 5 months after intracerebroventricular (i.c.v.) injection at age P2 (postnatal day 2) with
viral vectors inducing astrocyte-specific expression of EGFP (AAV8-GFAP-EGFP) or Cre (AAV8-GFAP-CreGFP). AAV8-GFAP-GFP-infected cells show whole-cell
GFP expression and persistent colocalized nuclear BMAL1 staining, while AAV8-GFAP-Cre infected cells show nuclear GFP expression, increased GFAP
expression, and loss of nuclear BMAL1. Scale bar, 30 mm.
(G) Representative images (left) and quantification (right) illustrating increased percent area covered by GFAP+ astrocytes in cortex in mice from (F) injected with
AAV8-GFAP-Cre, as compared to AAV8-GFAP-GFP-injected controls. Note that AAV8-GFAP-Cre virus encodes a CreGFP fusion protein that is nuclear localized
and more difficult to see (F). Scale bar, 100 mm. Each data point represents 1 mouse.
(H) Representative images and quantification of percent area of GFAP staining from hippocampus of Aldh1l1-CreERT2+;Bmal1f/f and Aldh1l1-CreERT2+;Bmal1wt/flox
mice at 3 months (2 months after tamoxifen treatment),CAG-CreERT2+;Bmal1f/fmice at 4 months (2 months after tamoxifen treatment), and Bmal1f/f controls. Scale
bar, 100 mm.
All data representmean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by 2-tailed t tests (C) and (G) or 1-way ANOVA (H) with Holm-Sidak correction
for multiple comparisons when applicable.
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from 4-month-old NBmal1 KO and Cre- controls at 4-hr inter-
vals across one circadian cycle in constant darkness. Gfap
mRNA levels showed no circadian oscillation in control or
Cre+ mice and were elevated across the circadian cycle in
Cre+ mice. These findings were duplicated in other markers
of astrocyte activation, including Aqp4 and Mmp14 (Fig-
ure S3B). Thus, the astrogliosis phenotype in Bmal1 KOs is
not likely due to direct regulation of Gfap or other activation
markers by the clock.
To address potential mechanisms linking BMAL1 to astrocyte
activation, we performed pathway analysis on our NBmal1 KO
transcriptomic data using two bioinformatics tools: Ingenuity
Pathway Analysis (IPA) and Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) Bioinformatics Resources
6.8 (Huang et al., 2009). We analyzed an inclusive list consisting
of all transcripts that differed between control and NBmal1 KO at
6 p.m. with uncorrected p values < 0.01 (Table S1). IPA canonical
pathway analysis identified glutathione-mediated detoxification
Figure 3. BMAL1 Regulates Astrocyte Activation via a Glutathionylation-Dependent Mechanism
(A) Astrocyte-specific genes upregulated inNestin-Cre+;Bmal1f/f (NBmal1 KO) cortex and changes to the same genes in Per1/2mutmice. Transcripts upregulated
at least 2-fold in NBmal1 KO were compared to the top 200 astrocyte-specific genes (Zhang et al., 2014), and overlapping genes are displayed. Other notable
genes implicated in astrocyte activation and function were upregulated in NBmal1 KO cortex (bottom). The clock-controlled genes Dbp and Nr1d1 are direct
Bmal1 transcriptional targets.
(B) Expression of neurotoxic, neurotrophic, and pan-reactive astrocyte activation genes (Liddelow et al., 2017) in 5-month-old global Bmal1 KO versus
WT littermate hippocampus assayed by microfluidic qPCR. Each data point represents the average of 4 Bmal1 KO mice normalized to the average of 4 WT
littermates.
(C) Results from Ingenuity Pathway Analysis canonical pathway analysis of NBmal1 KOmicroarray data. Pathways related to glutathione homeostasis are colored
blue.
(D) Expression levels for downregulated glutathione-S-transferases in NBmal1 KO cortex versus Bmal1f/f controls. Expression levels in Per1/2mut cortex included
for comparison (based on microarray data).
(E) qPCR illustrating effect of glutathione manipulation on Gfap transcript levels following Bmal1 knockdown. WT primary astrocytes treated with control siRNA
(siSCR, gray bars) or siBmal1 (blue bars), with or without N-acetyl-cysteine (NAC; striped bars) to increase glutathione levels, or buthionine sulfoxime (BSO;
speckled bars) to deplete glutathione. n = 9 samples/condition from 3 separate experiments.
(F) WT astrocytes transfected with siSCR, siBmal1, or siSCR +BSO (BSO) were treated with biotin-linked glutathione ethyl ester (bioGEE) to assess gluta-
thionylation. Increased band intensity indicates decreased endogenous glutathionylation. Arrows denote altered bands. NT, not treated with bioGEE, showing
nonspecific labeling.
(G) qPCR depicting effects of NAC treatment on Gfap transcript levels in cortex of inducible Bmal1 KO mice (CAG-CreERT2+;Bmal1f/f). Inducible Bmal1 KO mice
and Cre control littermates were treated with NAC before, during, and after 5-day tamoxifen treatment to delete Bmal1. Mice were harvested 9 days after the
start of tamoxifen. n = 6–10 mice per group.
All data represent mean + SEM. *p < 0.05, ***p < 0.001 by t test with Holm-Sidak correction for multiple comparisons.
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as the top hit (Figure 3C; p = 0.000013). Functional annotation
clustering with DAVID showed that the most enriched gene clus-
ter focused on glutathione-S-transferase (GST) activity, and 4 of
the top 5 Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways identified were related to glutathione metabolism (Fig-
ure S3C). GST enzymes catalyze the phase II detoxification of
reactive intermediates in cells via adduction to glutathione and
can alter cellular signaling via glutathionylation of proteins
(Grek et al., 2013). We found that expression of several GST iso-
forms was suppressed in NBmal1 KO cortex and increased in
Per1/2mut cortex (Figure 3D), suggesting reciprocal regulation
by the positive and negative limbs of the circadian clock. In
support of our microarray analysis, we observed significant
decreases in 2 of the 3 GST isoforms probed in cortex from
3-month-old CAG-Cre+;Bmal1f/f mice 9 days after tamoxifen
treatment (Figure S3D) and in 1 of the 3 GST isoforms probed
in hippocampus from 3-month-old Aldh1l1-Cre+mice 2 months
after tamoxifen treatment (Figure S3E). We next asked if altered
glutathione homeostasis within astrocytes linked Bmal1 defi-
ciency with astrocyte activation. Our data clearly show that
Bmal1 deletion induced changes in both Gfap mRNA and
GFAP protein, which are very closely correlated across all
models (see Figure S4A), so Gfap mRNA was used as a marker
for astrogliosis in subsequent experiments. Treatment with
N-acetyl cysteine (NAC), a glutathione precursor, completely
prevented increased Gfap expression in astrocytes following
Bmal1 KD (Figure 3E). Conversely, incubation of WT astrocytes
with buthionine sulfoxime (BSO), which blocks glutathione pro-
duction, lowered cellular glutathione levels (Figure S3F) and
caused an increase in Gfap mRNA similar to that observed
with Bmal1 KD (Figure 3E). Treatment of Bmal1-deficient astro-
cytes with BSO did not induce a further increase in Gfap, sug-
gesting that BSO and Bmal1 KD are causing increases in Gfap
through overlapping pathways. Interestingly, neither Bmal1 KO
nor KD of Bmal1 in cultured primary astrocytes altered gluta-
thione levels (Figure S3F). Additionally, the oxidation state of
glutathione (ratio of reduced GSH to oxidized GSSG) was not
altered in cortex fromNBmal1KOorPer1/2mutmice (Figure S3G).
As glutathione levels and oxidation state remained unchanged
with loss of Bmal1, we next examined glutathione signaling via
glutathionylation, which has been shown to oscillate in a circa-
dian manner in the SCN (Wang et al., 2012). Western blot anal-
ysis of WT astrocytes treated with biotin-linked glutathione ethyl
ester (bioGEE) revealed widespread changes in the pattern of
S-glutathionylated proteins inBmal1KD cells, whichwere similar
to changes seen in BSO-treated controls (Figure 3F). In general,
numerous bands showed increased biotin labeling, indicating
decreased glutathionylation, as would be expected with
decreased GST expression. These data suggest that the
observed astrogliosis may be due at least in part to altered pro-
tein glutathionylation resulting from impaired expression of spe-
cific GSTs.
We next examined whether bolstering glutathione signaling
can prevent astrogliosis followingBmal1 deletion in vivo. We pre-
viously showed that tamoxifen-inducible global Bmal1 deletion
in mice (CAG-Cre+;Bmal1f/f mice) causes astrocyte activation
(Yang et al., 2016). We treated CAG-Cre+;Bmal1f/f mice with
NAC in their drinking water (40 mM beginning 5 days before
tamoxifen) and via intraperitoneal injection (150 mg/kg daily
beginning 2 days before tamoxifen) and induced Bmal1 deletion
via tamoxifen administration for 5 days. Both administrations of
NAC were continued for the duration of the experiment. Cortex
was harvested 9 days after the start of tamoxifen treatment
and analyzed by qPCR. Tamoxifen treatment induced an 87%
loss in Bmal1 and a 79% loss in expression of the Bmal1 target
Nr1d1 (Figure S3H), as well as a 64% increase ifGfap expression
(Figure 3G). Administration of NAC was able to provide a signif-
icant but partial rescue of the Gfap increase seen in CAG-
Cre+;Bmal1f/f animals (Figure 3G). These results suggest that
Bmal1 regulates Gfap expression at least in part through modu-
lation of glutathione signaling in vivo.
Finally, we examined potential pathogenic consequences of
Bmal1 deletion in astrocytes. We generated primary astrocyte-
enriched cultures from CAG-Cre+;Bmal1f/f mice and Cre litter-
mates and treated them with tamoxifen in vitro to delete Bmal1.
These cultures are primarily astrocytes, but this methods yields
cultures which contain 2% microglia and/or oligodendrocyte
precursor cells (Schildge et al., 2013). Primary WT cortical neu-
rons were then co-cultured on these astrocytes for up to
12 days, and a subset was subjected to oxidative stress by
hydrogen peroxide exposure (100 mMH2O2) for 24 hr (Figure 4A).
We found no difference in the number of neurons surviving on
Cre and Cre+ astrocyte cultures 1 day after plating (as quanti-
fied by staining for neuronal nuclei with NeuN, as these cells do
not yet have many MAP2 positive neurites) (Figure 4B). At day 7
after plating, there was a 45%decrease in NeuN+ nuclei (Figures
4B and 4C), a trend toward a decrease in MAP2 staining, and a
trend toward an increase in cleaved-caspase-3 staining (Figures
S4B and S4C) in the Cre+ astrocyte condition. The decrease in
MAP2 staining in cultures containing Cre+ astrocytes became
significant after 12 days (Figures 4D and 4E). H2O2 exposure
at day 12 decreased MAP2 levels in Cre cultures, and the
combination of Bmal1 deletion and H2O2 killed nearly all neurons
(Figures 4D and 4E). This finding shows that Bmal1-deficient as-
trocytes are less able to sustain neuronal viability, particularly in
the face of oxidative stress.
DISCUSSION
Despite a large body of evidence describing circadian disrup-
tions in both aging and neurodegenerative disease, little is
known about the implications of circadian dysfunction on the
brain. Here, we provide evidence that behavioral circadian
disruption or disruption of the astrocytic molecular clock via ma-
nipulations of the master clock gene Bmal1 induce astrogliosis
and astrocyte dysfunction. The critical but complex role of astro-
cytes in brain pathologies and neuroinflammation underscores
the importance of elucidating mechanisms of astrocyte activa-
tion, and our data illuminate BMAL1 as a potent regulator of
astrocyte activation by both cell-autonomous and non-autono-
mous mechanisms.
The existence of the astrocyte circadian clock has been well
documented (Prolo et al., 2005), and the critical role of the astro-
cyte clock in maintaining circadian rhythms in the SCN has
recently been described (Barca-Mayo et al., 2017; Brancaccio
et al., 2017; Tso et al., 2017). Clock genes have been shown to
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regulate astrocytic glutamate uptake and ATP release (Beaule´
et al., 2009; Marpegan et al., 2011), but the function of the core
clock in astrocytes is otherwise unexplored. We have shown
here, using several in vitro and in vivo methods, that loss of
Bmal1 function in astrocytes causes cell-autonomous astrocyte
activation. However, deletion of Bmal1 specifically in neurons
also induces a partial astrocyte activation phenotype, suggest-
ing a coexistent cell-non-autonomous mechanism. Bmal1 dele-
tion in cultured neurons causes toxicity (Musiek et al., 2013),
implicating a possible damage signal from Bmal1-deficient neu-
rons that activates nearby astrocytes. Alternatively, the neuron-
specific Bmal1 KO mice used in this study are behaviorally
arrhythmic (Izumo et al., 2014), and this loss of rhythms could
induce astrocyte activation, as seen in 10 hr:10 hr L:D-exposed
animals (Figure 1). Thus, cell-non-autonomous influences on
glial activation in the brain must be examined in the future.
One important question is whether the loss of rhythmic func-
tion of the circadian clock plays a key role in this phenotype or
if this is a ‘‘non-circadian’’ function of BMAL1. Our data suggest
that arrhythmicity in the setting of increased BMAL1 expression,
as in Per1/2mut mice, does not induce astrocyte activation, as
these mice express increased levels of GSTs. Thus, astrocyte
activation appears to be dependent on suppression of BMAL1-
mediated transcription. However, BMAL1 DNA binding is highly
rhythmic and regulated by the clock (Koike et al., 2012), making it
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Figure 4. Loss of Bmal1 Impairs Astrocytic
Support of Neurons
(A) Diagram depicting co-culture experimental
design. DIV, days in vitro; TAM, tamoxifen.
(B) Representative images showing NeuN+ WT
neuronal nuclei at DIV 1 and 7, grown on primary
astrocytes from Cre control mice, or inducible
Bmal1 KO mice (iCAG-Cre+) treated with tamox-
ifen in vitro. Scale bar, 100 mm.
(C) Quantification of NeuN+ nuclei from (B)
normalized to NeuN counts from Cre condition.
n = 8 replicates from 2 independent experiments.
(D) Representative images of MAP2+ WT neurons
grown as in (B) at DIV 12. Lower panels show
neurons from adjacent wells treated for 24 hr with
hydrogen peroxide at DIV 11 (H2O2, 100 mM).
Scale bar, 100 mm.
(E) Quantification of MAP2 immunoreactivity
(percent area) from (D). n = 9 replicates from 3
independent experiments.
All data represent mean ± SEM. *p < 0.05, **p <
0.01 by 2-tailed t test.
difficult to separate entirely from circa-
dian rhythms. Bmal1 KD in astrocytes ab-
rogates circadian Per2-luc oscillations,
which could contribute to increased
Gfap expression in cell culture. Moreover,
we show in Figure 1 that circadian disrup-
tion by exposure of mice to 10 hr:10 hr
L:D conditions, which blunts Bmal1 oscil-
lations in the brain, can induce Gfap
expression. Thus, dampening the rhyth-
micity of BMAL1 expression through
circadian clock disruption likely plays a role in mediating astro-
gliosis, perhaps by restricting BMAL1 levels at certain key times
of day. BMAL1 levels can be suppressed by several factors such
as aging (Wyse and Coogan, 2010), inflammation (Curtis et al.,
2015), or amyloid-beta (Song et al., 2015), all of which could
potentially influence astrocyte activation and function in a
BMAL1-dependent manner.
The activation profile induced in Bmal1-deficient astrocytes
encompasses upregulation of a variety of genes across the pre-
defined neurotoxic, neurotrophic, and pan-reactive categories
(Liddelow et al., 2017). However, it is important to remember
that these astrocyte phenotypes are thought to be induced by
cytokine release from microglia, whereas activation due to loss
of Bmal1 can be cell autonomous. Our findings contrast with
those of Nakazato et al., who found that S100b-Cre+;Bmal1f/f
mice did not develop astrocyte activation and attributed the
astrocyte activation phenotype of Nestin-Cre+;Bmal1f/f mice to
pericyte dysfunction (Nakazato et al., 2017). While our data do
not exclude a contribution of blood-brain barrier dysfunction to
the Nestin-Bmal1 phenotype, we provide multiple lines of evi-
dence demonstrating cell-autonomous astrocyte activation.
While Bmal1-deficient astrocytes do not assume a clear neuro-
toxic (‘‘A1’’) phenotype, they are less able to support neuronal
survival in a co-culture system and express numerous tran-
scripts associated with inflammation and neurodegeneration.
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These include C4b, a complement component and marker of
astrocyte activation and aging (Boisvert et al., 2018; Clarke
et al., 2018), Megf10, which mediates astrocytic synapse
elimination (Chung et al., 2013), and Pla2g3, a phospholipase
implicated in ROS-induced neuronal damage (Martı´nez-Garcı´a
et al., 2010). Activation marker Lcn2 (lipocalin 2), an anti-inflam-
matory mediator in the brain (Kang et al., 2018), was not
increased, again suggesting a pro-inflammatory state.
Our data support a mechanism in which loss of BMAL1 in-
duces astrogliosis through disruption of GST-mediated protein
glutathionylation. In addition to its role in quenching oxidative
stress, glutathione can form adducts on cysteine residues in a
process termed glutathionylation, which is catalyzed by GSTs
and can serve a signaling function (Grek et al., 2013; Mailloux
and Treberg, 2016). Circadian rhythms of protein S-glutathiony-
lation in the SCN may regulate neuronal excitability (Wang et al.,
2012). Because Bmal1-deficient astrocytes have normal total
glutathione levels, it is likely that disruption of GST-mediated
glutathione signaling or utilization, but not glutathione depletion,
mediates BMAL1-controlled astrogliosis. Accordingly, we
observed an altered pattern of protein S-glutathionylation in
Bmal1-deficient astrocytes, which resembled that seen in
BSO-treated cells. Thus, supplementing Bmal1-deficient astro-
cyte cultures or mice with NAC presumably prevents astrogliosis
by promoting nonenzymatic glutathionylation of protein targets,
thereby circumventing the loss of GSTs. Further studies are
needed to identify specific glutathionylation targets that mediate
astrocyte activation and understand regulation of astrocyte
glutathione signaling in health and disease.
In summary, our data identify the circadian clock protein
BMAL1 as a cell-autonomous regulator of astrocyte activation
and neurotrophic function and posit altered GST-mediated pro-
tein glutathionylation as a mediator of this effect. Our findings
suggest that BMAL1 serves as a link between the core circadian
clock and astrogliosis and provide insights into how the circa-
dian clock might influence neurodegeneration.
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B6.Cg-Tg(Nes-cre)1Kln/J (Nestin-Cre mice) Jackson Labs Cat# 003771
B6.129S4(Cg)-Arntltm1Weit/J (Bmal1f/f mice) Jackson Labs Cat# 007668
CamKIIalpha iCre BAC (CamK2a-Cre mice) Casanova et al., 2001 N/A
Oligonucleotides
SMARTpool ON-TARGETplus Arntl siRNA Dharmacon Cat# L-040483-01-0005
ON-TARGETplus Non-targeting siRNA1 Dharmacon Cat# D-001810-02-05
Gfap Taqman Gene expression assay Applied Biosystems Mm01253033_m1
Actb Taqman Gene expression assay Applied Biosystems Mm02619580_g1
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Serpina3n Taqman Gene expression assay Applied Biosystems Mm00776439_m1
S100a6 Taqman Gene expression assay Applied Biosystems Mm00771682_g1
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Musiek (musieke@wustl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Nestin-Cre+, CAG-CreERT2+, Global Bmal1 KO, Aldh1L1-CreERT2+, and Bmal1f/f mice were obtained from The Jackson Laboratory
(Bar Harbor, ME) and were bred at Washington University. Camk2a-iCre+;Bmal1f/f mice were bred at University of Texas South-
western. All cohorts of mice were mixed sex with ages specified in figure legends. All mice were backcrossed at least 10 generations
and were maintained on a C57Bly6 background and housed under 12-hour light/12-hour dark conditions. In all cases, a Cre+;
Bmal1f/fmale mouse was bred with Bmal1f/f females to generate an equal mix of Cre- and Cre+ mice, all on the Bmal1f/f background.
All littermates were thus used for experiments. Aldh1L1-CreERT2+ and CAG-CreERT2+ mice (Cre- and Cre+ littermates from
several litters) were given tamoxifen (Sigma, dissolved in corn oil, 2mg/mouse/day for 5 days) by oral gavage at 1mo or 2mo,
respectively, to induce Bmal1 deletion in the applicable tissue. Behavioral circadian desynchronization experiments were performed
at Washington State University, using adult male C57BL/6N mice (age 5-6 weeks on arrival, Harlan Envigo). All mice were group
housed for gene expression experiments (N = 4-5 per cage), or singly housed for actigraphy, with food and water available ad libitum.
All mouse experiments were conducted in accordance with protocols approved by the Washington University Department of
Comparative Medicine, or by the IACUCs at UTSW or WSU.
Primary cell cultures
Primary cells were extracted frommixed sex P1-3 (astrocytes) or E16-17 (neurons) CD1WT,Bmal1f/f, or iCAG-Cre+;Bmal1f/f mice per
experimental designation. Wild-type (WT) CD1 mice for culture experiments were obtained from Charles River Laboratories
(Wilmington, MA). Mice were briefly anesthetized by cooling on ice, cleansed with ethanol, then decapitated with scissors, and
the brain placed in ice-cold DMEM (Life Technologies). Cortices were dissected, stripped of meninges in ice-cold DMEM, and incu-
bated in 0.05% Trypsin-EDTA (Life Technologies) at 37C for 15 (neurons) or 20 (astrocytes) minutes. 37C DMEM plus 10% FBS
(GIBCO) was then added to neutralize trypsin, cortices were spun down for 5 minutes at 300 g and gently triturated in 37C
DMEM plus 10% FBS (GIBCO). For astrocytes cultures, cells were then plated on 10cm or T75 tissue culture plates (coated for 2
hours at 37C with 50 mg/mL poly-D-lysine (PDL- MP Biosciences, Santa Ana, CA), then rinsed twice with ddH2O) at a concentration
of 2 cortices (1 brain) per plate. Astrocytes were then grown to confluence (10 days), then shaken at 37C in a heated shaker at
225 rpm for 2 hours, followed by media change to remove adherent microglia. Cells were later lifted using Trypl-E dissociation re-
agent (Life Technologies) for 5 minutes at 37C, washed with DMEM plus 10% FBS, and replated on 12-well (mRNA experiments),
Continued
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Il6 Taqman Gene expression assay Applied Biosystems Mm00446190_m1
Il33 Taqman Gene expression assay Applied Biosystems Mm00505403_m1
C4b Taqman Gene expression assay Applied Biosystems Mm00437893_g1
Cxcl5 Taqman Gene expression assay Applied Biosystems Mm00436451_g1
Mmp14 Taqman Gene expression assay Applied Biosystems Mm00485054_m1
Timp1 Taqman Gene expression assay Applied Biosystems Mm01341361_m1
Dbp Taqman Gene expression assay Applied Biosystems Mm00497539_m1
Gsta2 Taqman Gene expression assay Applied Biosystems Mm03019257_g1
Gsta4 Taqman Gene expression assay Applied Biosystems Mm00494803_m1
Gstt3 Taqman Gene expression assay Applied Biosystems Mm00519528_m1
Software and Algorithms
Ingenuity Pathway Analysis QIAGEN Build Version: 400896M; Content version
28820210
Imaris Bitplane Version 9
Prizm GraphPad Version 7
DAVID Bioinformatics Resource https://david.ncifcrf.gov/ Version 6.8
Fiji https://fiji.sc/ N/A
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48-well (neuronal co-cultures), or 96-well (GSH experiments) plates (coated with PDL as above) at a 1:2 dilution. Astrocyte-enriched
cultures were then grown in DMEM+ 10% FBS + penicillin/streptomycin until used for experiments.
METHOD DETAILS
Behavioral Desynchronization
Activity was monitored by implanted Mini-mitter telemetry device (Star BioSciences). For circadian desynchronization, mice were
transferred into a 20h light/dark cycle, with 10h of light (200 Lux) and 10h of dark for 6 weeks then harvested as described below
at CT0, 6, 12, and 18; N = 4-5/group/time.
Intracerebroventricular injections
Bmal1f/f mice were injected on postnatal day 2 (P2) with either AAV8-GFAP-GFP or AAV8-GFAP-CreGFP viral vectors (2 mL, bihemi-
spheric, fromUNC viral vector core), using a 30 gHamilton syringe (10ul, 45 degree bevel) with a cuff to ensure proper depth (1.5mm).
The injection site was 1mm lateral and 1mm posterior to bregma. Mice were housed as described above, harvested at 5 months of
age and analyzed as described in the immunohistochemisty section.
Immunohistochemistry
Mice were anesthetized by i.p. pentobarbital (150mg/kg), followed by perfusion for 3 minutes with ice-cold Dulbecco’smodified PBS
(DPBS) containing 3 g/l heparin. One hemisphere was post-fixed in 4%paraformaldehyde for 24 hours (4C), then cryoprotected with
30% sucrose in PBS (4C) for 48 hours. 50-micron serial coronal sections were then cut on a freezing sliding microtome and stored in
cryoprotectant solution (30% ethylene glycol, 15% sucrose, 15%phosphate buffer in ddH20). Sections were washed in Tris buffered
saline (TBS), blocked for 30 minutes in TBSX (TBS with 0.25% Triton X-100 (Sigma-Aldrich, St. Louis, MO)) containing 3% goat
serum, then incubated overnight in TBSX containing 1% goat serum plus primary antibody at 4C. Sections were then washed in
TBS, incubated for 1 hour at room temperature in TBSX with 1:1000 fluorescent secondary antibody, and mounted on slides using
Fluoromount G. Epiflourescent images were obtained on a Nikon Eclipse 80i fluorescent microscope. A Nikon A1Rsi scanning
confocal microscope was used at 20x for Ki67/GFAP co-localization, at 40x for Aldh1L1-Cre BMAL1/GFAP quantification, and at
60x for viral injection and representative Aldh1L1-Cre co-localization pictures.
Culture experiments
For neuronal cultures, triturated cells were transferred to a second tube to remove debris, then diluted in Neurobasal+B27+glutamine
(Life Technologies) and counted prior to plating on astrocyte beds. For co-culture experiments, astrocytes were grown to confluence
after replating in 48-well plates and neurons were added immediately following primary dissection at a concentration of 37,500 cells/
well in Neurobasalmedia plus B-27 supplement and glutamine. After 48 hours, 50%of themediawas changed toNeurobasal plus anti-
oxidant-free B-27 (AOFB-27, Life Technologies) and glutamine. Subsequently, 50%media changeswere performed usingNeurobasal
plus AOFB-27 and glutamine every 3 days until neuronal DIV 7 or 11. In cultures grown toDIV 11, half of thewells received 100 mMH2O2
for 24 hours. All wells were then fixed with 4% paraformaldehyde for 15 minutes, washed 3x with TBS and stained for MAP2, Cleaved-
Caspase-3 or NEUN and quantified using protocol in immunoreactivity quantification section.
Immunoreactivity quantification
GFAP and MAP2 staining were quantified from 10x images using ImageJ software (NIH). GFAP 8-bit images were thresholded by
hand to encompass all GFAP immunoreactivity, and a threshold value was set and maintained for all sections. GFAP percent
area coverage was then calculated for each image. In general, 1 image from each section and 2-3 sections/mouse were averaged,
and the average from each mouse used as a data point. For Ki67/GFAP co-localization, puncta were hand-counted from maximal
intensity projections of z stacks in each region of interest. GFAP, BMAL1, and DAPI co-localizations were hand counted by 2 inde-
pendent, blinded experimenters in 6 images/mouse (3 hippocampus, 3 cortex) with the average for each mouse reported. Cleaved-
Caspase-3 puncta co-localizing with MAP2 were hand counted by 2 independent, blinded experimenters in 3-5 images/well over 11
wells from 3 independent experiments with averages/well reported.
qPCR
Flash-frozen brain tissue was homogenized with a mechanical homogenizer for 20 s in RNA kit lysis buffer (PureLinkTM RNAMini Kit,
Life Technologies, Carlsbad CA) plus 1% b-mercaptoethanol. RNAwas then purified using the kit protocol. Cell lysates were homog-
enized in TRIzol (Life Technologies). The aqueous layer was then utilized, after chloroform extraction (added 1:5, sample then spun at
13000xg for 15 minutes), in RNA isolation using the kit protocol. RNA concentration was then measured by Nanodrop spectropho-
tometer and cDNAwasmade using a high capacity RNA-cDNA reverse transcription kit (Applied Biosystems/Life Technologies) with
1 mg RNA used per 20 mL reaction. Real-time quantitative PCR was performed with ABI TaqMan primers and ABI PCR Master Mix
buffer on either the ABI StepOnePLus or QuantStudio 12k Real-Time PCR thermocyclers. During analysis, mRNA measurements
were normalized to b-actin (Actb) mRNA levels. All Taqman qPCR primers were obtained from Thermo/Fisher.
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Microfluidic qPCRwas performed on flash frozen hippocampal tissue from 6moGlobal Bmal1 KO andWT littermatesmice at Stan-
ford University using a BioMark Real-Time PCR system (Fluidigm, South San Francisco, CA) and analyzed as previously described
(Liddelow et al., 2017).
Western blotting
Tissue samples were homogenized by sonication radioimmunoprecipitation (RIPA) buffer (Cell Signaling Technologies, Danvers MA)
containing cOmplete protease inhibitors (Roche Lifesceinces USA, Indianapolis IN). Invitrogen nuPAGE Novex gels, SDS running
buffer, and an iBlot transfer device were utilized per the manufacturer’s instructions (Life Technologies). Bands were visualized using
Lumigen TMA-6 chemiluminescence reagents (Lumigen, Southfield MI) on a Syngene GBOX imaging system. Band density was
calculated using ImageJ software and normalized to ERK as a loading control.
Microarray
11mo NBmal1 KO, Cre- littermate, and Per1/2mut mice were placed in constant darkness for 36 hours, then anesthetized with i.p.
pentobarbital in the dark, followed by perfusion. Mice were harvested at CT 6 and 18 (6am and 6pm), 2-4 mice/genotype/time point.
RNA was isolated from flash frozen cortex samples as above and submitted to the Genome Technology Access Center at Washing-
ton University for quality control, MessageAmp RNA library preparation, and Agilent 4x44k mouse v2 microarray. Raw data was
normalized and analyzed using Partek Genomics Suite v6.6. For DAVID analysis, version 6.8 was used. The gene list from Table
S1 was uploaded using Official Gene Symbol as the identifier, species = Mus musculus, and 692/842 genes were recognized.
Two analyses were run: Functional Annotation Clustering (stringency: high), and KEGG pathway analysis. For Ingenuity Pathway
Analysis (QIAGEN, Venlo, Netherlands), content version 28820210, build version 400896 was used, and the same gene list was em-
ployed (with ratios and p values). Cannonical Pathway analysis was performed. Dataset will be uploaded to GEO Datasets website
(https://www.ncbi.nlm.nih.gov/gds/).
siRNA transfections
Astrocytes were transfected with siRNA using lipofectamine RNAiMAX (Life Technologies) in Optimem (LifeTechnologies) according
to manufacturer’s instructions 24 hours after replating. After 48 hours, media was changed to DMEM plus 10% FBS. SiRNAs target-
ing mouse Bmal1 or non-targeting (designed to target no known mouse gene) were obtained from Dharmacon (Lafayette, CO). ON-
TARGETplus SmartPool siRNA was used, which contains 5 separate siRNAs targeting the gene of interest which are pooled together
(Bmal1: product L040483-01-005, non-targeting: D-001210-01-05). An siRNA:RNAiMAX ratio of 1:1.25) was used, and 40 pmol of
siRNA (2uL of 20uM stock) was added to each well, using 12-well plates. Media was changed 24-48 hours later.
BSO and NAC experiments
For NAC experiments, astrocytes were incubated in growth media supplement with 1mMN-acetylcysteine (Sigma) starting 24 hours
after transfection with siRNA, and for the remainder of the experiment. 72 hours before harvest, media was changed to DMEM plus
2%FBS and, where indicated, containing 250 mMbuthionine sulfoxime (BSO, Sigma) and cells were harvested as described above at
day 8 after siRNA treatment.
CAG-Cre+;Bmal1f/f mice and Cre- littermates (age 2-3 mo) used for in vivo NAC experiments were given either control drinking
water or water containing 40mM NAC starting day 0 until sacrifice. Beginning on day 3 and continuing until sacrifice, mice were
also given daily intraperitoneal injections of NAC (150mg/kg) or sterile DPBS for controls. Tamoxifen (Sigma, dissolved in corn oil,
2mg/mouse/day for 5 days) was administered by oral gavage to all mice beginning day 5 after water treatment. Water was refreshed
once at day 7. Mice were perfused at day 14 (4 days after completion of tamoxifen) and tissue was prepared as described above.
Per2:luciferase Bioluminescence Recording
Primary astrocyte cultures were prepared from P1-2 PER2::LUC transgenic mice, and transfected with siRNA as above. 48 hours
later, cells were synchronized by media change, and PER2::LUC activity was continuously monitored from a photomultiplier tube
(HC135-11MOD, Hamamatsu) from transfected cortical astrocytes plated on a sealed 35mm Primaria dish (BD Biosystems, San
Diego, CA) with 1 mL of serum-free DMEM supplemented with 2% B27 (Invitrogen), pen/strep, 10 mM HEPES, 0.35 g/L NaHCO3,
4.5 g/L D-glucose, 2% L-glutamine, and 0.1 mM beetle luciferin (Promega,Madison,WI). Acquired in vitro bioluminescence traces
were detrended by division over a 24h running average and fitted with a damped sine function (Chronostar 2.0, PMID: 19299560).
Only traces with a coefficient of correlation > 0.80 and period between 18-30h were considered circadian and rhythmic.
BioGEE glutathionylation assay
Primary astrocyte cultures were prepared and transfected with siBmal1 and siSCR siRNA as described above. At day 5 post-trans-
fectionmedia was changed to DMEM, +2%FBS, +penicillin/streptomycin. Also at day 5, 250uMBSO (Sigma) was added to a subset
of wells to block glutathione synthesis. At day 7 post-transfection all media was refreshed (DMEM, +2% FBS, +penicillin/
streptomycin, +250uM BSO where appropriate) and 100uM BioGEE Glutathiolation Detection Reagent (Invitrogen, G36000) was
added to each well except for one (non-treated control). After 3 hours, cells were lysed in RIPA buffer and processed as in western
blotting section. As the entire size range of membrane was needed to blot for glutathione ethyl ester linked biotin, a parallel gel was
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run using the same sample mix in order to blot for loading control (p42/44 ERK). After transfer, the loading control membrane was
blotted and imaged as above in the western blotting section. The membrane for detection of glutathionylation was washed and
blocked as above except that TBS-T (tris buffered saline +0.125 tween) was replaced with PBS-T (phosphate buffered
saline +0.125% tween) per method recommendation. After blocking, membrane was placed in 5% milk in PBS-T +streptavidin
poly-HRP40 conjugate (Fitzgerald, Boston,MA, 65R-S104PHRP, 1:2000) for 1 hour, washed 5 times in PBS-T and imaged as in west-
ern blotting section.
Glutathione Measurements
GSH and GSSG levels were quantified in mouse cortex samples using the Glutathione Assay Kit (Cayman Chemical, Ann Arbor, MI).
In cell culture experiments, glutathione measurements were obtained at day 7 using the Intracellular Glutathione Detection Assay Kit
(Abcam, Cambridge, MA) by kinetic read (beginning immediately upon adding reagent and then every 5 minutes for 60 minutes) on a
Tecan Infinite M1000 Pro fluorescent plate reader (Tecan, Switzerland).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prizm v7.02. In general, data are represented by mean ± SEM. In mouse
experiments, ‘‘n’’ represents the number of mice and in cell culture experiments ‘‘n’’ represents the number of biological replicates.
Specific statistical tests used, p value level definitions, and additional details are listed in figure legends. When multiple t test were
performed, Holm-Sidak correction test for multiple comparisons was applied unless otherwise noted.
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data reported in this paper is ArrayExpress: E-MTAB-7151. Array available at https://www.
ebi.ac.uk/arrayexpress/experiments/E-MTAB-7151/
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Figure S1. Related to Figure 1; Characterization of mouse models with astrogliosis induced by loss of Bmal1.
A. Representative actigraph of a WT mouse housed in 12h:12h light:dark, then switched to 10h:10h light:dark at black 
arrow, leading to behavioral arrhythmicity.
B. Cortical qPCR showing mRNA levels from 10h:10h light:dark WT mice from Fig. 1A, S1A reveals increased Gfap
expression at most timepoints throughout the circadian day.
C. Hippocampal (top, scale bars = 150μm) and cortical (bottom, scale bars = 50μm) staining of NEUN (red) and 
BMAL1 (green) from 4mo Camk2a-iCre+;Bmalf/f mice and Cre- controls shows complete loss of neuronal BMAL1 in 
Cre+ animals. 
D. Representative images (top) and quantification (bottom) illustrating minimal localization of the cell division marker 
Ki67 staining with GFAP+ astrocytes in cerebral cortex from 4 mo Nestin-Cre+;Bmal1f/f (NBmal1 KO) mice (left 
graph), despite large increases in GFAP+ cells as compared to Cre- controls (right graph). Scale bar= 50μm.
E. NBmal1 KO mice have increased GFAP+ activated astrocytes in the cerebral cortex without major changes in 
number of total (S100B+) astrocytes. Scale bar = 50μm.






































































































































Figure S2. Related to Figure 2;  Characterization of astrogliosis seen with loss of Bmal1 in vitro and in vivo.
A. qPCR showing mRNA levels of several astrocyte activation and inflammatory genes 7 days after treatment of WT 
astrocytes with non-targeting siRNA (siSCR) or siRNA targeting Bmal1 (siBmal1). N=12-15 experiments. 
B. Representative cortical images from mice in Fig. 2F-H. Top row. AAV8-GFAP-GFP-infected cells (solid arrows) show 
whole-cell GFP expression, persistent colocalized nuclear BMAL1, and fail to colocalize with neuronal nuclei (hollow 
arrows). Bottom row. AAV8-GFAP-Cre infected cells show only nuclear GFP expression (solid arrows, CreeGFP fusion 
protein), loss of nuclear BMAL1 and fail to colocalize with neuronal nuclei (hollow arrows). Scale bar= 30µm.
C. Representative images, quantification of %GFAP area in retrosplenial cortex of mice in Fig. 2H. Scale bar = 100µm.
D. Representative confocal images of Aldh1l1-Cre+;Bmalf/f mice and Cre- controls. DAPI+, GFAP+ (solid arrows) 
astrocytes colocalize with BMAL1 in Cre- mice, but not in Cre+ mice. Scale bar= 30µm.
E. Quantification of DAPI/GFAP/BMAL1+ cells (top) or GFAP+ cells per field of view (bottom) in Aldh1l1-Cre+;Bmalf/f
mice vs Cre- controls in hippocampus.  Each data point = 1 mouse.  6 fields/mouse with an average of 24.5 GFAP+ 
cells/field, totaling 1,176 cells counted. Note that there is not an increase in GFAP+ cells in hippocampus, just the size 
and shape of these cells.
F. mRNA levels of astrocyte activation markers in hippocampus from Aldh1l1-Cre+;Bmalf/f mice vs Cre- controls. 
All data represent mean+SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by 2-tailed T-tests (A), (E), and (F) or 1-way 
ANOVA (D) with Hom-Sidak correction for multiple comparisons when applicable.
GFAP
Rank Category Term Count % PValue Genes Fold Enrich Benjamini FDR
1 KEGG_PATHWAY mmu00982:Drug metabolism ‐ cytochrome P450 11 1.590 2.76E‐05 GSTM1, GSTA2, FMO6, UGT1A6B, UGT1A6A, MAOB, AOX1, GSTT1, GSTT2, GSTT3, GSTM7 5.4290 0.0064 0.0355
2 KEGG_PATHWAY mmu00980:Metabolism of xenobiotics by cytochrome P450 9 1.301 6.84E‐04 GSTM1, GSTA2, UGT1A6B, UGT1A6A, HSD11B1, GSTT1, GSTT2, GSTT3, GSTM7 4.5807 0.0766 0.8746
3 KEGG_PATHWAY mmu05414:Dilated cardiomyopathy 9 1.301 0.00370693 ADCY3, ADCY2, ITGB8, CACNG5, IGF1, ITGA3, CACNA1F, TTN, CACNA1S 3.5321 0.2506 4.6591
4 KEGG_PATHWAY mmu00480:Glutathione metabolism 7 1.012 0.00634706 GSTM1, GSTA2, IDH2, GSTT1, GSTT2, GSTT3, GSTM7 4.1458 0.3099 7.8544
5 KEGG_PATHWAY mmu05204:Chemical carcinogenesis 9 1.301 0.0069225 GSTM1, GSTA2, UGT1A6B, UGT1A6A, HSD11B1, GSTT1, GSTT2, GSTT3, GSTM7 3.1866 0.2765 8.5376
6 KEGG_PATHWAY mmu00062:Fatty acid elongation 5 0.723 0.00749553 ACAA2, ELOVL2, ECHS1, ACOT1, ACOT5 6.2642 0.2534 9.2133
7 KEGG_PATHWAY mmu00350:Tyrosine metabolism 5 0.723 0.03032123 DCT, TYRP1, MAOB, AOX1, TPO 4.1761 0.6412 32.6699
8 KEGG_PATHWAY mmu04916:Melanogenesis 8 1.156 0.03153854 DCT, ADCY3, EDNRB, TCF7, WNT4, TYRP1, ADCY2, WNT3A 2.6322 0.6068 33.7477
9 KEGG_PATHWAY mmu05410:Hypertrophic cardiomyopathy (HCM) 7 1.012 0.03336309 ITGB8, CACNG5, IGF1, ITGA3, CACNA1F, TTN, CACNA1S 2.8863 0.5846 35.3335
10 KEGG_PATHWAY mmu05200:Pathways in cancer 20 2.890 0.03488911 BMP4, TRAF1, ADCY3, TCF7, COL4A2, COL4A1, ADCY2, WNT3A, IGF1, FGF23, ITGA3, BDKRB2, R 1.6410 0.5628 36.6328
11 KEGG_PATHWAY mmu04390:Hippo signaling pathway 10 1.445 0.04160489 BMP4, TCF7, WNT4, CCND2, WNT3A, GDF5, TEAD3, WWTR1, GLI2, BMP6 2.1572 0.5935 42.0699
12 KEGG_PATHWAY mmu05222:Small cell lung cancer 7 1.012 0.04310029 TRAF1, MAX, COL4A2, COL4A1, ITGA3, RB1, LAMB1 2.7145 0.5749 43.2204
13 KEGG_PATHWAY mmu04925:Aldosterone synthesis and secretion 7 1.012 0.04744608 ADCY3, ADCY2, CAMK1G, CAMK4, MC2R, CACNA1F, CACNA1S 2.6514 0.5816 46.4455
14 KEGG_PATHWAY mmu04020:Calcium signaling pathway 11 1.590 0.04901976 ADCY3, EDNRB, ADCY2, CAMK4, CYSLTR2, PHKG2, PLCD1, CACNA1F, BDKRB2, ITPKA, CACNA1S 1.9906 0.5668 47.5711
C
Figure S3. Related to Figure 3; Pathway analysis, GSTx, and GSH with Bmal1 deficiency.
A. Expression of BMAL1 transcriptional targets and Gfap from microarray in Fig. 3A at CT 6 and 18.
B. Expression of astrocyte activation transcripts Gfap, Aqp4, and Mmp14 in cortex of NBmal1 KO (Cre+, red) and Cre-
control mice (black) at 4 hour timepoints across the circadian cycle. No clear circadian oscillations were observed in 
Cre- or Cre+ mice. N=3-4 mice/genotype/timepoint.
C. KEGG pathway analysis of NBmal1 KO microarray data. Blue = pathways related to glutathione homeostasis.
D. qPCR of mRNA expression of glutathione transferases in the cortex of iCAG-Cre+;Bmal1f/f mice (Fig. 3F), 9 days 
after tamoxifen treatment, normalized to Cre-, Bmalf/f controls. 
E. qPCR of mRNA expression of glutathione transferases in hippocampus of Aldh1l1-Cre+;Bmal1f/f mice (Fig. 2H).
F. GSH levels in Bmal1 KO (top) and siBmal1 treated WT (bottom) astrocyte enriched cultures along with appropriate 
controls as measured by fluorometric intracellular glutathione detection assay.
G. Quantification of GSH and GSSG levels in cortical tissue (CT 10) from control, NBmal1 KO, and Per1/2mut mice. 
None of the averages were significantly different.
H. mRNA expression of Bmal1 and Nr1d1 in the cortex of iCAG-Cre+;Bmal1f/f mice used in Fig. 3G, 9 days after 
tamoxifen treatment, normalized to Cre-, Bmalf/f controls. 

















Figure S4. Related to Figures 3 and 4; Comparison of Gfap mRNA and GFAP protein across experiments; 
Further characterization of neuronal support deficits observed with loss of Bmal1.
A. Comparison of Gfap mRNA (quantified by qPCR) and GFAP protein (quantified by immunofluorescence) across 
experiments in this manuscript. Note that in both cultures cells and two distinct Cre-Lox mouse models, Gfap mRNA 
and GFAP protein are very closely related. Data is shown separately in Figs. 1 and 2.
B. Representative images showing MAP2+ (green) and cleaved-Caspase-3+ (CASP-3, red, arrows) WT neurons 
(grown as in Fig. 4A) at DIV 7. Scale bar = 100μm.
C. Quantification of MAP2 percent area (top) and cleaved-Caspase-3+ (bottom) neurons from (C) shows non-
significant trends toward decreased MAP2 and increased cleaved-Caspase-3+ neurons when neurons are plated on 
BMAL1-deficient astrocytes (Cre+).
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